Details for Patent: 7,776,895

Summary for Patent: 7,776,895

Title:	Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Abstract:	The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices.
Inventor(s):	Philip Charles Box, Diane Mary Coe, Brian Edgar Looker, Inderjit Singh Mann, Panayiotis Alexandrou Procopiou
Assignee:	Glaxo Group Ltd
Application Number:	US12/211,322
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery;

US Patent 7,776,895: Indacaterol Dry-Powder Inhaler Claims, Expiration, and Patent Landscape

US Patent 7,776,895 protects inhalers containing a dry-powder formulation of indacaterol, including specified indacaterol salts, particle sizes, and lactose-containing formulations. The patent does not broadly claim indacaterol as a chemical compound. Its enforceable scope is directed to an inhaler that contains the claimed dry powder.

The patent is associated with Novartis’ indacaterol inhalation products, including Arcapta Neohaler and indacaterol-containing combination products. Its principal commercial importance was as a formulation and device claim covering the delivery of indacaterol to the lung.

What drug and product does US 7,776,895 cover?

The compound identified in the claims is indacaterol, chemically described as:

4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol.

Indacaterol is a long-acting beta-2 adrenergic receptor agonist. In the United States, it was marketed as indacaterol maleate under the Arcapta Neohaler brand. It has also been used internationally in combination products such as indacaterol/glycopyrronium and indacaterol/mometasone.

Item	Information
Active ingredient	Indacaterol
Therapeutic class	Long-acting beta-2 adrenergic agonist
Primary US product	Arcapta Neohaler
FDA application	NDA 022383
Dosage form	Dry powder for oral inhalation
Patent	US 7,776,895
Patent holder/assignee	Novartis-related entity
Core protection	Inhaler containing dry-powder indacaterol
Relevant regulatory pathway	NDA and potential ANDA competition
Biologic status	Not applicable; indacaterol is a synthetic small molecule

What do the claims of US 7,776,895 protect?

Claims 1 and 7 are the two independent claims. They differ principally in the chemical form of indacaterol.

Claim 1: indacaterol or specified pharmaceutically acceptable salts

Claim 1 requires an inhaler having one or more containers containing a dry powder formulation comprising indacaterol or a pharmaceutically acceptable salt.

The required elements are cumulative:

1. An inhaler.
2. One or more containers associated with the inhaler.
3. A dry powder formulation in the container.
4. Indacaterol or a pharmaceutically acceptable salt in that formulation.
5. Delivery of the active compound to the lung.

The claim does not expressly require lactose, a particular particle-size range, a capsule, a blister, a reservoir, or a specific inhaler architecture.

The phrase "one or more containers" is broad enough to cover several common dry-powder configurations, including single-dose capsules, blister strips, and reservoir-based inhalers, assuming the product satisfies the remaining limitations.

Claims 2 through 4: named indacaterol salts

Claims 2, 3, and 4 narrow claim 1 to specified salts:

Claim	Salt limitation
Claim 2	Alpha-phenyl cinnamate salt
Claim 3	1-naphthoate salt
Claim 4	(R)-mandelate salt

These claims are narrower than claim 1. A product containing one of these salts may infringe the dependent claim if the product also satisfies the inhaler, container, and dry-powder limitations.

The salt claims do not independently cover the salt in every context. They remain tied to the claimed inhaler and dry-powder formulation.

Claims 5 and 6: particle size and lactose

Claim 5 limits the active compound to particles ranging from 1 micrometer to 10 micrometers. Claim 6 requires lactose in the dry powder formulation.

Claim	Added limitation	Commercial relevance
Claim 5	Indacaterol particles from 1 µm to 10 µm	Targets respirable inhalation particles
Claim 6	Lactose excipient	Covers a common carrier-based dry-powder formulation

Claims 5 and 6 depend on claim 1. A product outside the 1-to-10 µm range may avoid claim 5 but could still fall within claim 1. The same applies to lactose: absence of lactose does not necessarily avoid claim 1.

Claim 7: indacaterol triphenylacetate

Claim 7 independently claims an inhaler containing a dry powder formulation comprising indacaterol triphenyl acetate, also described in the claim as the triphenyl acetate salt.

This is a separate independent claim rather than a dependent limitation on claim 1. Its scope is narrower chemically, but it may provide a distinct infringement theory if the marketed product contains the specified salt.

Claims 8 and 9 further narrow claim 7 by adding:

• Particles ranging from 1 µm to 10 µm; and
• Lactose in the dry powder formulation.

How broad is the enforceable scope?

The strongest practical feature of claim 1 is that it does not require lactose or a particular particle size. A competing product could use a different carrier, different particle engineering, or a different inhaler mechanism and still face claim 1 if it contains indacaterol in a dry powder inhaler.

The principal limitations are:

• The formulation must be dry powder.
• The product must be an inhaler.
• The formulation must be present in one or more containers.
• The compound must be indacaterol or a claimed pharmaceutically acceptable salt.
• The claimed use is delivery to the lung.

The patent therefore does not cover:

• Oral tablets containing indacaterol.
• Nebulized liquid solutions, unless the product also meets the dry-powder limitations.
• Injectable indacaterol formulations.
• Indacaterol-free inhalers.
• A chemical composition of indacaterol divorced from an inhaler.
• A formulation that contains a different beta-2 agonist rather than indacaterol.

The claim language is product-focused. It does not require the accused manufacturer to market the product under a particular brand or to use a particular dosing schedule.

What formulations are protected by US 7,776,895?

The patent reaches multiple formulation designs if the core limitations are met.

Formulation type	Potential claim relevance
Indacaterol dry powder in a capsule	Claim 1
Indacaterol dry powder in a blister	Claim 1
Indacaterol dry powder in a reservoir	Claim 1
Indacaterol with lactose	Claims 1 and 6
Indacaterol particles from 1 to 10 µm	Claims 1 and 5
Alpha-phenyl cinnamate salt	Claims 1 and 2
1-naphthoate salt	Claims 1 and 3
(R)-mandelate salt	Claims 1 and 4
Triphenylacetate salt	Claim 7
Triphenylacetate with 1-to-10 µm particles	Claims 7 and 8
Triphenylacetate with lactose	Claims 7 and 9

A formulation patent analysis must distinguish the active pharmaceutical ingredient from the salt and the finished dosage form. A generic manufacturer could attempt to design around the patent by selecting a different salt, a non-dry-powder dosage form, or an alternative active ingredient. Those strategies may still encounter separate patents covering indacaterol chemistry, manufacturing, dosage strength, device operation, or combination therapy.

When does US 7,776,895 lose exclusivity?

The patent’s 20-year term is measured from the applicable earliest effective US filing date under 35 U.S.C. §154. Public patent records associate the family with a December 22, 2003 priority date, producing a base term ending December 22, 2023 or, depending on the effective US filing and term-adjustment calculation, a later date in 2024.

The commonly reported expiration date for US 7,776,895 is December 22, 2024. The operative date depends on the USPTO term-adjustment calculation and any applicable patent-term extension. The patent should therefore be treated as a late-2024 expiration asset, subject to the official USPTO record.[1]

Milestone	Date or status
Earliest reported priority	December 22, 2003
US patent issue	August 17, 2010
Reported base expiration	December 22, 2024
Patent-term adjustment	Must be confirmed in USPTO Patent Center
Current strategic significance	Expiration and post-expiration freedom-to-operate analysis

There is no biosimilar exclusivity issue because indacaterol is a small-molecule drug. Competition would generally proceed through an ANDA or, for a materially different formulation, a 505(b)(2) application.

What is the Orange Book status of US 7,776,895?

US 7,776,895 was associated with Arcapta Neohaler and its NDA record. Orange Book relevance depends on whether the patent remained listed for the relevant NDA and whether the listing remained active at the time of an ANDA certification.[2]

For an ANDA applicant, the principal certification issue would have been:

• Paragraph IV: the patent is invalid, unenforceable, or not infringed; or
• Paragraph III: the applicant accepts delayed approval until patent expiration.

Because the claims are directed to an inhaler and dry powder formulation, a Paragraph IV challenge would likely focus on:

1. Claim construction of "inhaler."
2. Whether the proposed product contains a claimed indacaterol salt.
3. Whether the dosage form is a "dry powder formulation."
4. Whether the formulation is present in a claimed container.
5. Whether particle size is relevant to the asserted claim.
6. Whether the patent claims are anticipated or obvious over prior inhaled beta-2 agonist formulations.

A Paragraph IV certification directed to claim 1 would be more commercially significant than a challenge limited to claims 5, 6, 8, or 9, because claim 1 does not require lactose or a specified particle size.

Which companies are challenging indacaterol patent protection?

Publicly available information does not establish a broad, active US litigation campaign against US 7,776,895 that can be stated reliably without a current court-docket and FDA Orange Book review. The relevant competitive group consists of:

• Generic inhaler manufacturers pursuing indacaterol or indacaterol-containing products.
• Companies developing 505(b)(2) inhaled formulations.
• Manufacturers of alternative long-acting beta-2 agonists.
• Originator companies protecting combination products containing indacaterol.

Potential competitors face a product-specific rather than purely molecule-specific analysis. A company may avoid one claim by changing the salt or inhaler configuration but remain exposed to separate formulation, device, or combination-product patents.

What patent landscape surrounds indacaterol?

The relevant landscape has several layers.

Core compound patents

Earlier patent families may claim substituted phenethylamine compounds, including indacaterol and related beta-2 agonists. These patents are separate from US 7,776,895 and may have earlier expiration dates.

Salt and solid-state patents

Indacaterol salt patents can cover:

• Specific counterions.
• Crystalline forms.
• Hydrates and solvates.
• Stability characteristics.
• Processes for preparing the salt.
• Particle engineering.

These patents can create manufacturing or formulation barriers even after a core compound patent expires.

Inhalation formulation patents

US 7,776,895 occupies this category. Related patents may concern:

• Dry-powder carriers.
• Lactose grades and carrier particle sizes.
• Micronized active particles.
• Blend uniformity.
• Dose-metering systems.
• Capsule or blister packaging.
• Moisture protection.
• Aerodynamic performance.

Device patents

A separate device estate may cover the inhaler itself, including:

• Capsule piercing.
• Powder deaggregation.
• Airflow pathways.
• Dose loading.
• Mouthpiece geometry.
• Counter mechanisms.
• Reservoir dispensing.

Freedom to operate requires a device claim review even if US 7,776,895 has expired.

Method-of-use patents

Indacaterol products may also be covered by patents directed to:

• Once-daily bronchodilation.
• Chronic obstructive pulmonary disease treatment.
• Asthma treatment.
• Combination treatment with an inhaled corticosteroid.
• Combination treatment with a long-acting muscarinic antagonist.

US 7,776,895 is not principally a method-of-use patent. Its claims are directed to the inhaler and formulation.

Combination-product patents

Indacaterol has been commercialized with other active ingredients. Combination products may encounter separate patent families covering:

• Indacaterol/glycopyrronium.
• Indacaterol/mometasone.
• Indacaterol and inhaled corticosteroids.
• Fixed-dose combination ratios.
• Sequential or concurrent administration.

These patents can extend commercial protection beyond the expiration of a single-agent dry-powder patent.

How does US 7,776,895 compare with a typical generic launch risk?

Risk category	Assessment
API risk	Depends on separate indacaterol compound and salt patents
Formulation risk	Material before expiration because claim 1 is broad
Device risk	Separate inhaler patents may remain relevant
Lactose design-around	Does not avoid claim 1 by itself
Particle-size design-around	Does not avoid claim 1 by itself
Salt substitution	May avoid narrow salt claims, but not necessarily claim 1
Liquid formulation	Stronger design-around if it avoids dry-powder limitations
Combination-product risk	Potentially high because separate patents may apply
Biosimilar risk	None
ANDA litigation risk	Historically linked to Paragraph IV analysis
Post-expiration risk	Primarily device, combination, manufacturing, and regulatory barriers

The broadest practical risk is claim 1. A competitor cannot assume that changing lactose, particle size, or the inhaler mechanism avoids infringement. Those features are dependent limitations. The most meaningful design-around options are likely to involve a non-dry-powder dosage form, a different active ingredient, or a formulation that does not contain indacaterol or a covered salt.

Were there licensing deals or settlements?

A definitive assessment of licensing agreements, covenant-not-to-sue arrangements, or Paragraph IV settlements requires review of FDA settlement disclosures, SEC filings, and federal court dockets. No specific settlement involving US 7,776,895 should be treated as established solely from the issued claims.

Originator licensing is more likely to arise at the product or regional portfolio level than through a license limited to this single patent. Relevant commercial arrangements may cover indacaterol, inhaler technology, combination products, or geographic rights.

What is the commercial exposure?

US 7,776,895 protected a product with limited standalone commercial positioning relative to newer combination inhalers. Arcapta Neohaler was a single-agent indacaterol product, while indacaterol combinations became more important in the long-acting respiratory market.

The patent’s commercial value therefore depended on:

• Arcapta sales before expiration.
• The extent to which the patent covered generic versions of the inhaler.
• Continued sales of indacaterol combination products.
• Separate device and combination patents.
• Regulatory substitution and formulary access.
• The availability of competing LABA products such as formoterol, salmeterol, olodaterol, and vilanterol.

Patent expiration does not automatically create immediate market entry. An entrant still needs FDA approval, a substitutable device and dose presentation, manufacturing capacity, and a viable formulation with acceptable aerodynamic performance.

Key Takeaways

1. US 7,776,895 is an inhaler and dry-powder formulation patent for indacaterol.
2. Claim 1 is the central claim and does not require lactose, a particular particle size, or a specific inhaler design.
3. Claims 2 through 4 cover named indacaterol salts.
4. Claims 5 and 6 add particle-size and lactose limitations.
5. Claim 7 separately covers indacaterol triphenylacetate in a dry-powder inhaler.
6. The patent does not broadly claim indacaterol as a chemical compound.
7. The commonly reported expiration date is December 22, 2024, subject to the USPTO’s final term calculation.
8. Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
9. Separate compound, salt, device, manufacturing, method-of-use, and combination-product patents may affect launch timing.
10. After expiration, the main residual barriers are regulatory approval, device patents, manufacturing know-how, and combination-product protection.

FAQs on US 7,776,895 and indacaterol patent protection

Does US 7,776,895 cover indacaterol maleate?

Claim 1 covers indacaterol or a pharmaceutically acceptable salt in a dry-powder inhaler. Indacaterol maleate may fall within the broad salt language if the other claim elements are satisfied, although the patent’s expressly named dependent claims identify different salts.

Can a generic avoid US 7,776,895 by removing lactose?

Not necessarily. Lactose is required only by claim 6. Claim 1 does not require lactose, so a lactose-free dry powder may still fall within claim 1.

Can a generic avoid the patent by changing particle size?

Changing particle size may avoid claim 5 or claim 8 if the product is outside the claimed range. It does not automatically avoid claims 1 or 7, which do not require a 1-to-10 micrometer particle size.

Is US 7,776,895 a method-of-use patent?

No. The claims are directed primarily to an inhaler containing a dry-powder formulation of indacaterol or a specified salt. Separate method-of-use patents may cover treatment of COPD, asthma, or combination therapy.

Does expiration of US 7,776,895 clear all indacaterol launch risk?

No. A launch may still face separate patents covering the indacaterol molecule, salt or crystalline form, inhaler device, manufacturing process, combination product, or approved method of use.

References

1. United States Patent and Trademark Office. (2010). US Patent No. 7,776,895, inhaler containing dry powder formulation of indacaterol. USPTO Patent Center.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2011). Arcapta Neohaler (indacaterol maleate) prescribing information. FDA.
4. United States Code, 35 U.S.C. §154. Patent term.
5. United States Code, 21 U.S.C. §355(j). Abbreviated new drug applications and patent certifications.

Drugs Protected by US Patent 7,776,895

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,776,895

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0122201.7	Sep 14, 2001
United Kingdom	0126997.6	Nov 09, 2001

International Family Members for US Patent 7,776,895

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1425001		CR 2014 00021	Denmark
European Patent Office	1425001		C01425001/02	Switzerland
European Patent Office	1425001		CA 2014 00021	Denmark
European Patent Office	1425001		C300664	Netherlands
European Patent Office	1425001		PA2014019	Lithuania
European Patent Office	1425001		92439	Luxembourg
European Patent Office	1425001		C20140013 00103	Estonia